HEMLIBRA® is approved for hemophilia A with or without FVIII inhibitors

See Prescribing Information.

Indication

HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.

FVIII=factor VIII.

National Broadcast

Register to learn more about the expanded indication of HEMLIBRA airing on Thursday, October 18, 2018.
Use one of the codes below:
7:00pm ET: PRF87072-P
9:00pm ET: PRF87073-P

Dosing Calculator 

Help calculate the dosage for your HEMLIBRA patient

Mechanism of Action

How HEMLIBRA may work in patients with hemophilia A with or without FVIII inhibitors